HIV-2
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS [1]
Mutations associated with resistance | Mutations associated with « possible resistance » | |
ZDV | ![]() ![]() | ![]() |
3TC/FTC | ![]() | ![]() |
ABC | ![]() ![]() ![]() | ![]() |
TDF/TAF | ![]() ![]() |
ZDV: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ABC: abacavir, TDF: tenofovir, TAF : tenofovir alafenamide
Didanosine and stavudine are not recommended.
PROTEASE INHIBITORS [1]
Mutations associated with resistance | Mutations associated with « possible resistance » | |
LPV | ![]() ![]() ![]() | ![]() ![]() |
DRV | ![]() ![]() ![]() | ![]() |
LPV: lopinavir, DRV : darunavir
For indinavir and saquinavir refer to previous rules (Version 27, September 2017).
Atazanavir and tipranavir are not recommended.
INTEGRASE STRAND TRANSFER INHIBITORS [1]
Mutations associated with resistance | Mutations associated with « possible resistance » | |
RAL | ![]() ![]() ![]() ![]() ![]() | ![]() ![]() |
EVG | ![]() ![]() ![]() ![]() ![]() | ![]() |
DTG | ![]() ![]() ![]() ![]() ![]() | ![]() ![]() ![]() ![]() |
CAB* | ![]() ![]() ![]() ![]() ![]() | ![]() ![]() ![]() ![]() |
BIC* | ![]() ![]() ![]() ![]() | ![]() ![]() ![]() ![]() ![]() |
RAL: raltegravir, EVG : elvitegravir, DTG: dolutegravir, CAB: cabotegravir, BIC: bictegravir
*Due to the very close structures of dolutegravir and cabotegravir, rules for dolutegravir are transposed to cabotegravir with the exception of the insertion at codon 231 for bictegravir.
NON-nuclEosidE REVERSE TRANSCRIPTASE INHIBITORS
![]() |
FUSION INHIBITOR
![]() |
ATTACHMENT INHIBITOR
![]() |
1/ Charpentier C et al. HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update. Clin Infect Dis. 2015 Jul 17. pii: civ572.
2/ Witvrouw E et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9(1): 57-65.
3/ Smith RA et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS ONE, 2012; 7.
4/ Smith RA, In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.01299-18. doi: 10.1128/AAC.01299-18.
5/ Le Hingrat Q et al. A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors. 16th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, May 2018, Roma, Italy, Abstract 4.
6/ Lataillade M et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment
inhibitor prodrug, Fostemsavir. J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):299-30